Genovis AB (GENO)

Overview

Founded in 1999 and based in Lund, Sweden, Genovis AB (publ.) is at the forefront of developing innovative tools aimed at revolutionizing treatment methods and diagnostics within the pharmaceutical and medical device industries. The company's commitment to advancing healthcare is evident in its broad range of products designed to cater to various aspects of pharmaceutical and biotechnological research and development. By serving a diverse clientele that spans across pharmaceutical and biotech companies, contract research organizations, and contract manufacturing companies, Genovis AB underscores its global footprint not just in its native Sweden, but across Europe, North America, and Asia. Through its dedicated online store, the company ensures that its groundbreaking products are easily accessible to its worldwide customer base.

Products and Services

• FabALACTICA: A cysteine protease specifically designed to digest human IgG1 antibodies.
• FabRICATOR: Known for its ability to digest the hinge region of IgG antibodies, allowing for the separation of these molecules into distinct fragments.
• FabRICATOR Z: Tailored for the digestion of mouse IgG2a and IgG3 antibodies, it facilitates the generation of a homogenous pool of F(ab')2 and Fc fragments.
• FabULOUS (SpeB): An enzyme targeting the digestion of IgG in the hinge region to create consistent and predictable antibody fragments.
• GingisKHAN: Another cysteine protease, but specifically engineered for the effective digestion of human IgG1.
• FabDELLO: Focuses on the precise digestion of human IgG1 to aid in detailed structural and functional antibody studies.
• GingisREX: A cysteine protease renowned for its specificity in digesting peptide bonds C-terminally to the specified sites.
• GlySERIAS: Developed to cleave flexible glycine-rich fusion protein linkers, streamlining the purification or modification processes.
• GlyCLICK: Represents a conjugation technology engineered for site-specific and quantitative IgG conjugation, enhancing the precision of antibody-drug conjugates.
• TransGLYCIT: A platform technology enabling site-specific remodeling of human IgG glycans, crucial for adjusting effector functions or improving stability.
• OmniGLYZOR: Offers a combination of immobilized enzymes for broad application in glycan remodeling or analysis.
• PNGase F: A glycoamidase that hydrolyzes the amide bond between the polypeptide asparagine and the innermost GlcNAc, essential for N-glycan analysis.
• OpeRATOR: Specialized as an O-glycan-specific protease, it aids in the detailed analysis and modification of glycoproteins.
• OglyZOR: Acts as an endoglycosidase for the removal of O-linked glycans, facilitating studies on protein structure and function.
• SialEXO, FucosEXO, GalactEXO, GalNAcEXO: A suite of enzymes designed for the specific removal of sialic acids, fucoses, galactoses, and N-acetylgalactosamines, respectively, aiding in the precise modification and analysis of glycoproteins and glycopeptides.
• GlycOCATCH: An affinity resin that enables the purification of mucin-type O-glycosylated proteins and peptides, important for studies on mucin-like glycoproteins.
• GlycINATOR (EndoS2) & IgGZERO (EndoS): Both are IgG-specific endoglycosidases, with the former being specific for certain glycoforms, crucial in the modulation of antibody effector functions.
• Anti-FabRICATOR (Anti-IdeS) & Anti-FabRICATOR Z (Anti-IdeZ): Comprise goat polyclonal antibodies against the respective enzymes, useful in immunoassays and enzyme inhibition studies.